Dynamic Technology Lab Private Ltd Takes $926,000 Position in Bio-Rad Laboratories, Inc. $BIO

Dynamic Technology Lab Private Ltd bought a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 3,301 shares of the medical research company’s stock, valued at approximately $926,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of BIO. Quent Capital LLC bought a new stake in Bio-Rad Laboratories in the third quarter worth $25,000. Farther Finance Advisors LLC raised its stake in shares of Bio-Rad Laboratories by 52.9% in the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 36 shares during the period. Geneos Wealth Management Inc. lifted its holdings in shares of Bio-Rad Laboratories by 115.2% in the 2nd quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares during the last quarter. CWM LLC lifted its holdings in shares of Bio-Rad Laboratories by 82.0% in the 3rd quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after acquiring an additional 91 shares during the last quarter. Finally, UMB Bank n.a. boosted its stake in shares of Bio-Rad Laboratories by 24.0% during the 3rd quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock worth $58,000 after purchasing an additional 40 shares during the period. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Stock Down 3.2%

Shares of BIO opened at $270.00 on Monday. The firm has a fifty day moving average price of $295.78 and a 200-day moving average price of $301.28. The company has a current ratio of 5.62, a quick ratio of 4.19 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $7.29 billion, a P/E ratio of 9.67 and a beta of 1.18. Bio-Rad Laboratories, Inc. has a 12-month low of $211.43 and a 12-month high of $343.12.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 12th. The medical research company reported $2.51 earnings per share for the quarter, missing analysts’ consensus estimates of $2.57 by ($0.06). The company had revenue of $693.20 million for the quarter, compared to the consensus estimate of $694.64 million. Bio-Rad Laboratories had a net margin of 29.42% and a return on equity of 3.86%. The company’s quarterly revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $2.90 EPS. Equities research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on BIO. Wall Street Zen lowered shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a research report on Monday, December 29th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $358.50.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.